Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection

Abstract

Bortezomib therapy: (1) provides effective treatment of AMR and ACR with minimal toxicity and (2) provides sustained reduction in iDSA and non-iDSA levels. Bortezomib represents the first effective antihumoral therapy with activity in humans that targets plasma cells.